Merck Sharp & Dohme LLC acquisition of Cidara Therapeutics, Inc.

Merck Sharp & Dohme LLC completed its acquisition of Cidara Therapeutics, Inc. on 2026-01-07, according to the Form 8-K Cidara Therapeutics, Inc. filed with the SEC on 2026-01-07. The filing's Item 2.01 states no aggregate dollar price. Cidara Therapeutics, Inc. filed the report because the deal made it part of Merck Sharp & Dohme LLC.

Want the whole picture on Merck Sharp & Dohme LLC?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Merck Sharp & Dohme LLC: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Merck Sharp & Dohme LLC covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   1 cited source found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

What the filing says

Upon completion of the Merger, the Company became a wholly owned subsidiary of Parent.

More from the filing

As previously disclosed in the Current Report on Form 8-K filed with the Securities and Exchange Commission (" SEC ") by Cidara Therapeutics, Inc., a Delaware corporation (the " Company ") on November 14, 2025, the Company entered into an Agreement and Plan of Merger, dated November 13, 2025 (the " Merger Agreement "), with Merck Sharp & Dohme LLC, a New Jersey limited liability company (" Parent "), and Caymus Purchaser, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (" Purchaser ").

Pursuant to the Merger Agreement, on December 5, 2025, Purchaser commenced a tender offer to acquire (i) all of the outstanding shares of common stock of the Company, par value $0.0001 per share (the " Common Shares "), for $221.50 per Common Share (the " Common Share Offer Price ") and (ii) all of the outstanding shares of Series A Convertible Voting Preferred Stock of the Company, par value $0.0001 per share (the " Series A Shares " and together with the Common Shares, the " Shares "), for $15,505.00 per Series A Share (the " Series A Offer Price "), in each case, in cash, without interest a

The Offer and withdrawal rights expired as scheduled at one minute following 11:59 p.m., Eastern Time, on January 6, 2026 (such date and time, the " Expiration Time ").

Quoted from Cidara Therapeutics, Inc.'s Form 8-K.

This is the only completed acquisition Merck Sharp & Dohme LLC reported under Item 2.01 in the last twelve months, as far as the filings of the companies it bought show.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.

Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.

All recent acquisitions